Group 1: Store Operations and Profit Growth - New stores begin normal operations from the third month, achieving profitability by the 12th month and fully recovering losses by the 26th month [1] - The company's overall profit has grown by approximately 30% over the past three years, primarily due to the maturation of existing stores and enhanced management capabilities [2] Group 2: Gross Margin and Supplier Relationships - High gross margins are achieved through various supplier cooperation models, including national and regional distribution, which significantly impact profit margins [2] - Direct procurement from manufacturers allows the company to earn both channel and retail margins, further increasing overall profitability [3] Group 3: O2O Development and E-commerce Strategy - The company is exploring O2O business models and has partnered with SAP Hybris and Infosys Lodestone to enhance its e-commerce capabilities [4] - The official website features nearly 3,000 products across various categories, including Western and traditional Chinese medicine, medical devices, and health supplements [4] - The company has established three online stores on Tmall, maintaining good ratings in service and delivery [5] Group 4: Product Strategy and Market Positioning - The company focuses on providing affordable traditional Chinese medicine, sourcing raw materials directly from origin to minimize costs [6] - The "Cordyceps and Ginseng" store is designed as a flagship for traditional Chinese medicine, differing in product structure and customer targeting from standard pharmacies [7]

云南鸿翔一心堂药业（集团）股份有限公司 投资者调研会议记录 时间：2014 年 9 月 19 日 地点：云南鸿翔一心堂药业（集团）股份有限公司会议室 召开方式：电话访谈交流 投资者：光大证券等 25 人 接待人：公司董事、 董事会秘书、副总裁、财务负责人 田俊 参加人员：证券事务代表、证券总监 代四顺，信息总监兼平台 电商事业部总经理 李文程 一、公司情况介绍（田俊） 公司在公告中披露了在电商业务中的进展，公司开展电商比较早，拿证比较早，在官 网、淘宝、天猫、OTO 四个渠道都有进展。以 SAP 系统为核心，可以说公司是开展电商最早 的公司之一，SAP 系统在中国电商中使用较多，以一心堂最早使用，其他医药电商也有使 用。现在和大家探讨下医药电商行业的发展。 二、问答环节 1. 田总如何看待目前医药电商行业的发展情况？ 答：电商要有耐心，医药电商现在规模 46 亿，行业 2400 亿，2%不到。明年预测 68 亿， 占比 2%。OTO 替代率在 5%以下，医药销售还是以线下为主。美国医疗线下销售 83%，网 上替代网下 17%。并且线上部分也不全是邮寄，还有很大部分是店面取药。并且美国政策 上是医药分家，利于网 ...

云南鸿翔一心堂药业（集团）股份有限公司 投资者调研会议记录 时间：2015 年 08 月 19 日 地点：云南鸿翔一心堂药业（集团）股份有限公司会议室 召开方式：现场交流 投资者：华创证券 王逸萌、沈晓瑜，交银施罗德基金 沈楠，兴 业全球基金 钟明 接待人：证券事务代表、证券总监 代四顺 参加人员: 证券副总监李正红、证券部经理阴贯香 问题一，公司收购情况介绍？ 答：公司今年四月份以来，进行了海南联合广安堂药品超市连锁经营有限公司 100% 股权收购、山西长城药品连锁有限公司门店收购、山西白家老药铺连锁药店有限公司门店收 购、晋中市泰来大药房有限公司门店收购、山西百姓平价大药房连锁有限公司门店收购、广 西百色博爱医药连锁有限公司门店收购、四川省蜀康医药连锁有限公司门店收购、四川省田 燕梅女士个体经营药店收购、桂林市桂杏霖春药房连锁有限公司门店收购。目前，海南公司 已完成工商变更，山西吕梁百姓平价、晋中泰来、山西白家老药铺三家已完成门店交接，其 他几家正在办理交接过程中。海南公司是二季度纳入上市公司合并报表范围，其他几个收 购项目是资产收购，销售会在收购主体公司下半年的损益中体现出来。截止到 2015 年 6 ...

Group 1: Investor Relations Activity - The activity involved a specific audience survey and a site visit [1] - Participants included representatives from various financial institutions such as Shenwan Hongyuan and Agricultural Bank of China [1] - The event took place on September 10, 2015, from 09:00 to 12:00 [1] Group 2: Company Representatives - Company representatives included the Secretary of the Board and Financial Officer Tian Jun, along with other key personnel [1] - The meeting was held in the conference room of Yunnan Hongxiang Yixintang Pharmaceutical (Group) Co., Ltd. [1] Group 3: Main Content of the Activity - The main focus was on business development discussions and site tours [1] - A record of questions and discussions from the site visit was documented [1]

Group 1: Investor Relations Activity - The investor relations activity was a telephone conference with specific target research [1] - The event involved 94 participants from various investment firms [1] - The meeting took place on August 15, 2015, from 20:00 to 22:00 [1] Group 2: Company Representatives - The meeting was hosted by Tian Jun, the Vice President and Financial Officer of Yunnan Hongxiang Yixintang Pharmaceutical Group [1] - Other company representatives included board members and the board secretary [1] Group 3: Meeting Content - The main topics discussed included the company's mid-year report and progress on mergers and acquisitions [1] - Meeting materials included minutes and a list of participating units [1]

Group 1: Industry Trends - The Chinese pharmacy sector is expected to evolve towards concentration, platformization, and ecological integration, similar to trends observed in the U.S. market [1][2] - 80% of hospital prescription drug shares are projected to shift to drug retail terminals, creating significant growth opportunities [1] - The market is witnessing a shift from traditional retail to platform-based service models, integrating healthcare, pharmaceuticals, and testing services [2] Group 2: Competitive Landscape - Small pharmacies face increasing operational difficulties due to rising costs and competition, leading to potential mergers and acquisitions [1] - The industry is experiencing a scarcity of investment targets, with companies like Yunnan Hongxiang Yixin Hall, Yifeng Pharmacy, and Lao Baixing being highlighted as key players [3] - The market is characterized by high competition and a need for scale, with many small pharmacies likely to seek consolidation [4] Group 3: Business Models and Strategies - The future of pharmacies is centered around O2O (Online to Offline) models, leveraging both online and offline services to enhance customer engagement [2][6] - Yifeng Pharmacy operates 881 stores and emphasizes meticulous management and rapid integration through acquisitions [5] - The focus on member sales is crucial, with 70-80% of sales coming from membership interactions, necessitating upgrades to member management systems [5][8] Group 4: Regulatory Environment - The regulatory landscape is becoming more favorable for large chain pharmacies, with the removal of distance restrictions and encouragement for consolidation [7] - The healthcare reform is pushing for better integration of pharmacies with hospitals, enhancing service delivery through remote consultations and partnerships [6][10] - The insurance qualification landscape varies significantly, with Yunnan Hongxiang Yixin Hall having 39% and Yifeng Pharmacy 29% of their stores qualified for insurance [11]

投资者关系活动记录表 证券代码：002727 证券简称：一心堂 云南鸿翔一心堂药业（集团）股份有限公司投资者关系活动记录表 编号：TG1511-002 | --- | --- | --- | |-----------------------------|--------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | ■ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | | 兴业全球基金管理有限公司 杨世进 | | 人员姓名 | | | | 时间 | 2015 年 11 月 | 12 日 13： 30 至 14：30 | | 地点 | | 云南鸿翔一心堂药业（集团）股份有限公司会议室 | | | | | | 上市公司接待人 | | 董秘兼财务负责人 田俊、证券副总监 李正 ...

投资者关系活动记录表 证券代码：002727 证券简称：一心堂 云南鸿翔一心堂药业（集团）股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|----------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 ■分析师会议 | | 类别 | □ | 媒体采访 ■业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | | 兴业证券孙媛媛、陈晓威、中信证券,国信证券 , 益丰大药房王 | | 人员姓名 | | 总、老百姓大药房张总、方盛制药肖总、九洲大药房苏总、人民 | | | 同泰程总等 175 | 人（具体名单见附件） | | 时间 | 2015 年 11 月 | 11 日 15： 00 至 17：20 | | 地点 | | 云南鸿翔一心堂药业（集团）股份有限 ...

Group 1: Talent Development - The company ensures talent development through external recruitment, enhanced employee training systems, and internal promotion mechanisms [2] - A training center is established for new employee onboarding, cultural training, and various levels of management training [2] - Online learning systems are introduced to keep staff updated with the latest pharmaceutical knowledge [2] Group 2: Marketing System - A professional marketing planning team is established to ensure sales targets are met [3] - Collaboration with suppliers for market promotion enhances the marketing strategy [3] - The establishment of Yunnan Sanse Space Advertising Co., Ltd. focuses on marketing planning and implementation [3] Group 3: Membership Management - The company has cultivated a stable member base through effective management practices [4] - A dedicated membership management system safeguards member rights and fosters strong customer relationships [4] - The implementation of a CRM system aims to enhance customer data management and support decision-making [4] Group 4: Supply Chain Management - Long-term partnerships with well-known pharmaceutical manufacturers and wholesalers improve supply chain stability [5] - Efforts to enhance relationships within the supply chain have led to reduced procurement costs [5] - The company benefits from favorable supply prices and resource support [5] Group 5: Standardization Management - A comprehensive standardization process is in place for store development, from market research to employee training [6] - Standardized procedures govern store management, including inventory management and customer service [6] - Market analysis and marketing activities are conducted under strict standardized protocols [6]

云南鸿翔一心堂药业（集团）股份有限公司 投资者调研会议记录 时间：2015 年 11 月 25 日 地点：云南鸿翔一心堂药业（集团）股份有限公司会议室 召开方式：现场交流 投资者：华商基金 陈恒、何奇峰 接待人：董秘兼财务负责人 田俊 参加人员:证券事务代表兼证券总监 代四顺 问题一，执业药师是药店行业发展的必备专业型人才，公司对人才方面是如果规划的？ 答：执业药师是药店必备的专业型人才，是国家对药店监管方面的严格要求。药店必 须要配备执业药师方可销售药品，针对国家监管的要求以及目前执业药师专业型人才的稀 缺，各省药品监管部门根据当地的实际情况也出台了相应措施。如执业药师可以多点执业 已缓解药店对执业药师专业型人才的需求。同时公司在发展过程中积极向社会招聘有专业 技能的执业药师，针对企业员工积极开展专业培训，帮助和鼓励员工参加考试取得执业药 师资格，目前也取得很好的成效。 问题二，医保前置审批是否会取消？ 答：国务院已发布取消医保定点资格的审批，取消医保定点资格的审批并不意味着所 有的药店都可以刷医保进行消费购药。各地方政府根据当地实际情况，也会有自己的策略 和思路。单店是否能够刷医保，重点在于门店与医保信息 ...